Trial · NCT02500641
Adverse events182
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
21 to 40 of 182
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Blood thyroid stimulating hormone increased | Investigations | Febuxostat 80/120 mg/Day | 2 | 98 | 2 |
| other | Blood thyroid stimulating hormone increased | Investigations | Allopurinol 100 up to 600 mg/Day | 0 | 98 | 0 |
| other | Blood triglycerides increased | Investigations | Febuxostat 80/120 mg/Day | 2 | 98 | 2 |
| other | Blood triglycerides increased | Investigations | Allopurinol 100 up to 600 mg/Day | 3 | 98 | 3 |
| other | Blood uric acid increased | Investigations | Febuxostat 80/120 mg/Day | 1 | 98 | 1 |
| other | Blood uric acid increased | Investigations | Allopurinol 100 up to 600 mg/Day | 0 | 98 | 0 |
| other | C-reactive protein increased | Investigations | Febuxostat 80/120 mg/Day | 1 | 98 | 1 |
| other | C-reactive protein increased | Investigations | Allopurinol 100 up to 600 mg/Day | 0 | 98 | 0 |
| other | eosinophil count decreased | Investigations | Febuxostat 80/120 mg/Day | 1 | 98 | 1 |
| other | eosinophil count decreased | Investigations | Allopurinol 100 up to 600 mg/Day | 0 | 98 | 0 |
| other | Gamma-glutamyltransferase increased | Investigations | Febuxostat 80/120 mg/Day | 1 | 98 | 1 |
| other | Gamma-glutamyltransferase increased | Investigations | Allopurinol 100 up to 600 mg/Day | 3 | 98 | 3 |
| other | Heamoglobin decreased | Investigations | Febuxostat 80/120 mg/Day | 1 | 98 | 1 |
| other | Heamoglobin decreased | Investigations | Allopurinol 100 up to 600 mg/Day | 2 | 98 | 2 |
| other | Hepatic enzyme increased | Investigations | Febuxostat 80/120 mg/Day | 4 | 98 | 4 |
| other | Hepatic enzyme increased | Investigations | Allopurinol 100 up to 600 mg/Day | 1 | 98 | 1 |
| other | Laboratory test abnormal | Investigations | Febuxostat 80/120 mg/Day | 2 | 98 | 2 |
| other | Laboratory test abnormal | Investigations | Allopurinol 100 up to 600 mg/Day | 2 | 98 | 2 |
| other | Blood insulin decreased | Investigations | Febuxostat 80/120 mg/Day | 0 | 98 | 0 |
| other | Blood insulin decreased | Investigations | Allopurinol 100 up to 600 mg/Day | 2 | 98 | 2 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02500641/events?page=2